期刊
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
卷 876, 期 2, 页码 277-282出版社
ELSEVIER
DOI: 10.1016/j.jchromb.2008.10.055
关键词
Oxaliplatin; HPLC; Mass spectrometry
资金
- National Cancer Institute of Canada Clinical Trials Group
A HPLC-tandem mass spectrometry method was developed and validated for the quantitation of intact oxaliplatin in human plasma. Plasma ultrafiltrates were precipitated with acetonitrile and separation was performed on a 250 mm Beckman ODS reverse phase column using a gradient mobile phase. The mass spectrometer was operated in positive ionization mode using TurboionSpray and p recursor-production combinations of m/z 391.1 -> 305.1 and 371.1 -> 247.0 were monitored for oxaliplatin and carboplatin, the internal standard, respectively. The lower limit of quantitation for oxaliplatin was 20 ng/ml. The linear range of the method was 20-1000 ng/ml. The between- and within-day relative standard deviations ranged from 3.1 to 7.7%, and accuracy was within 5%. This method was successfully applied in a clinical study of oxaliplatin. (C) 2008 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据